Ibrutinib Restores Tumor-specific Adaptive Immunity in Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is characterized by early and profound immune suppression and reversal of these effects is essential to improve patient outcome. Targeted therapy with small-molecule inhibitors such as ibrutinib is highly effective and tolerable. Emerging data suggest that patients...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2021-08, Vol.27 (16), p.4465-4467
1. Verfasser:	Zent, Clive S
Format:	Artikel
Sprache:	eng
Schlagworte:	Adaptive Immunity Adenine - analogs & derivatives Humans Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Piperidines Pyrazoles Pyrimidines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Chronic lymphocytic leukemia (CLL) is characterized by early and profound immune suppression and reversal of these effects is essential to improve patient outcome. Targeted therapy with small-molecule inhibitors such as ibrutinib is highly effective and tolerable. Emerging data suggest that patients with CLL responding to ibrutinib therapy can recover anti-CLL adaptive immune cytotoxicity. .
ISSN:	1078-0432 1557-3265
DOI:	10.1158/1078-0432.CCR-21-1589